{"id":80038,"date":"2025-02-07T07:08:52","date_gmt":"2025-02-07T07:08:52","guid":{"rendered":"https:\/\/www.taxresearch.org.uk\/Blog\/?p=80038"},"modified":"2025-02-07T07:08:52","modified_gmt":"2025-02-07T07:08:52","slug":"drugs-galore","status":"publish","type":"post","link":"https:\/\/www.taxresearch.org.uk\/Blog\/2025\/02\/07\/drugs-galore\/","title":{"rendered":"Drugs galore"},"content":{"rendered":"<p>As if to reinforce the point <a href=\"https:\/\/www.taxresearch.org.uk\/Blog\/2025\/02\/07\/are-drug-companies-putting-profits-ahead-of-curing-people\/\" target=\"_blank\" rel=\"noopener\">in today's video<\/a>, I noticed this <a href=\"https:\/\/www.ft.com\/content\/473180e3-735b-40c3-91d1-0188ee08109f?shareType=nongift\" target=\"_blank\" rel=\"noopener\">in the FT<\/a> yesterday:<\/p>\n<blockquote><p>GSK launched a rare \u00a32bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, including cancer and HIV drugs, sending shares up as much as 6 per cent on Wednesday.<\/p>\n<p>Shareholders will also benefit from higher dividends, with the payout set to rise to 61p per share for the 2024 financial year, up from 58p last year, after the drugmaker reported an increase in annual sales. The FTSE 100 group raised its long-term annual sales forecast to more than \u00a340bn by 2031, up from a previous forecast of more than \u00a338bn.<\/p><\/blockquote>\n<p>As I argue in the video, curing diseases provides no benefit to a drug company. Creating drugs that have to be taken for life to manage a disease - which continues to afflict the sufferer - does, however, provide a massive boost to their profitability. I think GSK proves the point.<\/p>\n<p>In my opinion, big pharma really does not want to cure people. Managing them in their sickness is much more profitable for them. No wonder NHS costs are increasing.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>As if to reinforce the point in today&#8217;s video, I noticed this in the FT yesterday: GSK launched a rare \u00a32bn share buyback and raised<br \/><a class=\"moretag\" href=\"https:\/\/www.taxresearch.org.uk\/Blog\/2025\/02\/07\/drugs-galore\/\"><em> Read the full article&#8230;<\/em><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35,16,87,128],"tags":[],"class_list":["post-80038","post","type-post","status-publish","format-standard","hentry","category-economics","category-ethics","category-health","category-nhs"],"_links":{"self":[{"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/posts\/80038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/comments?post=80038"}],"version-history":[{"count":3,"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/posts\/80038\/revisions"}],"predecessor-version":[{"id":80064,"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/posts\/80038\/revisions\/80064"}],"wp:attachment":[{"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/media?parent=80038"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/categories?post=80038"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.taxresearch.org.uk\/Blog\/wp-json\/wp\/v2\/tags?post=80038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}